Fiona Lawrence

General Counsel bei ARECOR THERAPEUTICS PLC

Consumer Services

Health Technology

Health Services

Profil

Fiona Jane Lawrence is currently the VP-Clinical Development & Regulatory Affairs at Arecor Therapeutics Plc.
Previously, she worked as the Director-Research & Clinical Development at Duchenne UK, Senior Manager-Clinical Research at Prosensa Therapeutics BV, Commercial Trials Manager at Cambridge University Hospitals NHS Foundation Trust, and Senior Manager-Clinical Research at BioMarin Nederland BV.
Ms. Lawrence has an undergraduate degree from the University of Bath and a graduate degree from the University of Surrey.

Aktive Positionen von Fiona Lawrence

Unternehmen	Position	Beginn
ARECOR THERAPEUTICS PLC	General Counsel	-

Alle aktiven Positionen von Fiona Lawrence

Ehemalige bekannte Positionen von Fiona Lawrence

Unternehmen	Position	Ende
Cambridge University Hospitals NHS Foundation Trust Cambridge University Hospitals NHS Foundation Trust Hospital/Nursing ManagementHealth Services Operates hospitals that provides cardiology, cancer, pediatric and radiology services	Corporate Officer/Principal	-
BioMarin Nederland BV BioMarin Nederland BV The company is based in Amsterdam, the Netherlands. The Dutch company focuses on creating therapies—including gene therapies, biologics, small molecules, and antisense oligonucleotides—that target the underlying genetic causes of conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), neuronal ceroid lipofuscinosis type 2 (CLN2), alpha-1 antitrypsin deficiency (AATD), and Duchenne muscular dystrophy (DMD). BioMarin has developed eight approved medicines and maintains a pipeline of clinical and preclinical candidates across multiple therapeutic areas, including central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology. The company operates biologics and gene therapy manufacturing facilities certified for environmental and occupational health standards. Its website provides healthcare professionals in the EU with scientific publications, product and pipeline information, clinical trial listings, and resources for medical inquiries, adverse event reporting, and product complaints. BioMarin Nederland BV is the Dutch branch of BioMarin Pharmaceutical Inc., a biotechnology company founded in 1997 that specializes in developing medicines for serious, life-threatening genetic and rare diseases.	Corporate Officer/Principal	-
Prosensa Therapeutics BV Prosensa Therapeutics BV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company	Corporate Officer/Principal	-
Duchenne UK Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Operates as charitable trust to fund and accelerate treatments and cure for muscular dystrophy	Technik-/Wissenschafts-/F&E-Leiter	-

Sehen Sie sich die Erfahrung von Fiona Lawrence im Detail an

Ausbildung von Fiona Lawrence

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Fiona Lawrence im Detail an

Unternehmensverbindungen

Private Unternehmen	7
University of Bath University of Bath Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Surrey University of Surrey Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Prosensa Therapeutics BV Prosensa Therapeutics BV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company	Health Technology
Cambridge University Hospitals NHS Foundation Trust Cambridge University Hospitals NHS Foundation Trust Hospital/Nursing ManagementHealth Services Operates hospitals that provides cardiology, cancer, pediatric and radiology services	Health Services
BioMarin Nederland BV BioMarin Nederland BV The company is based in Amsterdam, the Netherlands. The Dutch company focuses on creating therapies—including gene therapies, biologics, small molecules, and antisense oligonucleotides—that target the underlying genetic causes of conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), neuronal ceroid lipofuscinosis type 2 (CLN2), alpha-1 antitrypsin deficiency (AATD), and Duchenne muscular dystrophy (DMD). BioMarin has developed eight approved medicines and maintains a pipeline of clinical and preclinical candidates across multiple therapeutic areas, including central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology. The company operates biologics and gene therapy manufacturing facilities certified for environmental and occupational health standards. Its website provides healthcare professionals in the EU with scientific publications, product and pipeline information, clinical trial listings, and resources for medical inquiries, adverse event reporting, and product complaints. BioMarin Nederland BV is the Dutch branch of BioMarin Pharmaceutical Inc., a biotechnology company founded in 1997 that specializes in developing medicines for serious, life-threatening genetic and rare diseases.
Duchenne UK Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Operates as charitable trust to fund and accelerate treatments and cure for muscular dystrophy	Miscellaneous
Arecor Therapeutics Plc Arecor Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops therapeutic products in diabetes	Health Technology